We are live on ! Find out more
ATNM icon

Actinium Pharmaceuticals
ATNM

45 hedge funds and large institutions have $3.12M invested in Actinium Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 7

13% more funds holding

Funds holding: 40 → 45 (+5)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 7

0.23% less ownership

Funds ownership: 0.52% → 0.29% (-0.23%)

46% less capital invested

Capital invested by funds: $5.8M → $3.12M (-$2.68M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1K

Holders
45
Holders Change
+5
Holders Change %
+12.5%
% of All Funds
0.89%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
12
Increased
7
Reduced
7
Closed
7
Calls
–
Puts
$1K
Net Calls
-$1K
Net Calls Change
-$1K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$161K
2
Renaissance Technologies
Renaissance Technologies
New York
+$113K
3
VF
Virtu Financial
New York
+$70K
4
UBS Group
UBS Group
Switzerland
+$21.9K
5
Jane Street
Jane Street
New York
+$14K

Top Sellers

Rank Fund Capital Flow
1
SCM
Sio Capital Management
New York
-$1.38M
2
SM
Sabby Management
Florida
-$1.27M
3
ECM
Endurant Capital Management
California
-$156K
4
OC
Oppenheimer & Co
New York
-$53.2K
5
Citadel Advisors
Citadel Advisors
Florida
-$35K
Name Holding Trade Value Shares
Change 		Change in
Stake
DY
26
Dowling & Yahnke
California
$5K – – –
HFM
27
Hartford Financial Management
Connecticut
$4K – – –
OC
28
Oppenheimer & Co
New York
$3K -$53.2K -7,709 -94%
Morgan Stanley
29
Morgan Stanley
New York
$3K -$297 -43 -9%
RJA
30
Raymond James & Associates
Florida
$3K – – –
SFWA
31
Summit Financial Wealth Advisors
Louisiana
$3K +$3.22K +467 New
Wells Fargo
32
Wells Fargo
California
$3K +$3.36K +487 New
TC
33
Truvestments Capital
Florida
$2K – – –
WS
34
Wedbush Securities
California
$2K – – –
WSFS
35
Wilmington Savings Fund Society
Delaware
$2K +$2.3K +333 New
TSS
36
Two Sigma Securities
New York
$2K +$2.6K +376 New
Bank of America
37
Bank of America
North Carolina
$1K -$3.82K -554 -80%
Northwestern Mutual Wealth Management
38
Northwestern Mutual Wealth Management
Wisconsin
$1K – – –
RG
39
Retirement Group
California
$1K +$545 +79 New
IA
40
IFP Advisors
Florida
$1K +$918 +133 New
Simplex Trading
41
Simplex Trading
Illinois
$1K +$1.15K +167 New
SCM
42
Sio Capital Management
New York
– -$1.38M -200,105 Closed
Citadel Advisors
43
Citadel Advisors
Florida
– -$35K -5,120 Closed
HF
44
HRT Financial
New York
– -$7K -1,074 Closed
Susquehanna International Group
45
Susquehanna International Group
Pennsylvania
– -$3K -369 Closed
BEAM
46
Baker Ellis Asset Management
Washington
– -$2K -333 Closed
FAM
47
Formidable Asset Management
Ohio
– -$2K -333 Closed
BRWM
48
B. Riley Wealth Management
Tennessee
– -$1K -200 Closed
Fidelity Investments
49
Fidelity Investments
Massachusetts
– +$41 +6 New
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
– +$41 +6 New
1
2
3

ATNM Hedge Fund Activity: Q4 2019 in Review

45 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q4 2019, worth a combined $3.12M — down 46% from $5.8M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ATNM positions and 7 closed out — a net gain of 5 holders — while 7 added to existing stakes and 7 trimmed.

The largest buyer was BlackRock, adding an estimated $161K. The largest seller was Sio Capital Management, exiting entirely with an estimated $1.38M sold.

  • 45 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q4 2019, up from 40 in Q3 2019.
  • Funds reported $3.12M of Actinium Pharmaceuticals stock for Q4 2019, down 46% quarter-over-quarter.
  • 12 funds opened new Actinium Pharmaceuticals positions in Q4 2019 and 7 closed out, a net change of +5 holders.
  • The largest Actinium Pharmaceuticals buyer in Q4 2019 was BlackRock, an estimated $161K added.
  • The largest Actinium Pharmaceuticals seller in Q4 2019 was Sio Capital Management, an estimated $1.38M sold.

Based on aggregated 13F filings for Q4 2019.